Which actionable statements qualify as good practice statements in Covid-19 guidelines? A systematic appraisal

Omar Dewidar, Tamara Lotfi, Miranda Langendam, Elena Parmelli, Zuleika Saz Parkinson, Karla Solo, Derek K. Chu, Joseph L. Mathew, Elie A. Akl, Romina Brignardello-Petersen, Reem A. Mustafa, Lorenzo Moja, Alfonso Iorio, Yuan Chi, Carlos Canelo-Aybar, Tamara Kredo, Justine Karpusheff, Alexis F. Turgeon, Pablo Alonso-Coello, Wojtek WierciochAnnette Gerritsen, Miloslav Klugar, María Ximena Rojas, Peter Tugwell, Vivian Andrea Welch, Kevin Pottie, Zachary Munn, Robby Nieuwlaat, Nathan Ford, Adrienne Stevens, Joanne Khabsa, Zil Nasir, Grigorios I. Leontiadis, Joerg J. Meerpohl, Thomas Piggott, Amir Qaseem, Micayla Matthews, Holger J. Schünemann

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Abstract

Objectives: To evaluate the development and quality of actionable statements that qualify as good practice statements (GPS) reported in COVID-19 guidelines. Design and setting: Systematic review. We searched MEDLINE, MedSci, China National Knowledge Infrastructure (CNKI), databases of Grading of Recommendations Assessment, Development and Evaluation (GRADE) Guidelines, NICE, WHO and Guidelines International Network (GIN) from March 2020 to September 2021. We included original or adapted recommendations addressing any COVID-19 topic. Main outcome measures: We used GRADE Working Group criteria for assessing the appropriateness of issuing a GPS: (1) clear and actionable; (2) rationale necessitating the message for healthcare practice; (3) practicality of systematically searching for evidence; (4) likely net positive consequences from implementing the GPS and (5) clear link to the indirect evidence. We assessed guideline quality using the Appraisal of Guidelines for Research and Evaluation II tool. Results: 253 guidelines from 44 professional societies issued 3726 actionable statements. We classified 2375 (64%) as GPS; of which 27 (1%) were labelled as GPS by guideline developers. 5 (19%) were labelled as GPS by their authors but did not meet GPS criteria. Of the 2375 GPS, 85% were clear and actionable; 59% provided a rationale necessitating the message for healthcare practice, 24% reported the net positive consequences from implementing the GPS. Systematic collection of evidence was deemed impractical for 13% of the GPS, and 39% explained the chain of indirect evidence supporting GPS development. 173/2375 (7.3%) statements explicitly satisfied all five criteria. The guidelines' overall quality was poor regardless of the appropriateness of GPS development and labelling. Conclusions: Statements that qualify as GPS are common in COVID-19 guidelines but are characterised by unclear designation and development processes, and methodological weaknesses.
Original languageEnglish
Article numberejhpharm-2021-003164
Pages (from-to)361-369
Number of pages9
JournalBMJ evidence-based medicine
Volume27
Issue number6
Early online date2022
DOIs
Publication statusPublished - 15 Apr 2022

Keywords

  • COVID-19
  • Evidence-Based Practice
  • Health Services Research

Cite this